Wnt family ligands

Box5 TFA is a potent Wnt5a antagonist. Box5 TFA inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca 2+ release. Box5 TFA inhibits cell migration. Box5 TFA has the potential for the research of melanoma.Appearance:SolidIC50&amp Target:Wnt5aIn

Box5 TFA is a potent Wnt5a antagonist. Box5 TFA inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca 2+ release. Box5 TFA inhibits cell migration. Box5 TFA has the potential for the research of melanoma.Appearance:SolidIC50&amp Target:Wnt5aIn

Box5 TFA is a potent Wnt5a antagonist. Box5 TFA inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca 2+ release. Box5 TFA inhibits cell migration. Box5 TFA has the potential for the research of melanoma.Appearance:SolidIC50&amp Target:Wnt5aIn

BPN-15606 is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC 50 values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central

BPN-15606 is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC 50 values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central

BPN-15606 is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC 50 values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central

BPN-15606 is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC 50 values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central

BPN-15606 is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC 50 values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central

BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC 50 = 19 nM GSK3β IC 50 = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics ( K i = 4.2 nM, respectively). BRD0209 is a tricyclic

BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC 50 = 19 nM GSK3β IC 50 = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics ( K i = 4.2 nM, respectively). BRD0209 is a tricyclic

BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC 50 = 19 nM GSK3β IC 50 = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics ( K i = 4.2 nM, respectively). BRD0209 is a tricyclic

BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC 50 = 19 nM GSK3β IC 50 = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics ( K i = 4.2 nM, respectively). BRD0209 is a tricyclic